Remdesivir and tocilizumab: Mix or match.
作者信息
Akinosoglou Karolina, Velissaris Dimitris, Ziazias Dimitris, Davoulos Christos, Tousis Alexandros, Tsiotsios Konstantinos, Kalogeropoulou Christina, Spyridonidis Alexandros, Marangos Markos, Fligkou Foteini, Gogos Charalampos
机构信息
Department of Internal Medicine, University General Hospital of Patras, Patras, Greece.
Division of Infectious Diseases, University General Hospital of Patras, Patras, Greece.
出版信息
J Med Virol. 2021 Jan;93(1):56-58. doi: 10.1002/jmv.26117. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
Remdesivir and tocilizumab: Mix or match.瑞德西韦和托珠单抗：联合使用还是交替使用。
J Med Virol. 2021 Jan;93(1):56-58. doi: 10.1002/jmv.26117. Epub 2020 Jun 19.
2
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.实地记录：托珠单抗与瑞德西韦联合治疗重症新型冠状病毒肺炎合并细胞因子释放综合征1例
JMIR Public Health Surveill. 2021 May 19;7(5):e27609. doi: 10.2196/27609.
3
Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients.瑞德西韦和托珠单抗在重症 COVID-19 患者中应用的临床研究。
J Assoc Physicians India. 2021 Jul;69(7):14-19. doi: 10.0102/japi.2021.07.
4
Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution.瑞德西韦、静脉注射甲泼尼龙冲击疗法和托珠单抗联合治疗重症冠状病毒病的报告：单机构20例系列病例
Respir Investig. 2022 Jul;60(4):604-606. doi: 10.1016/j.resinv.2022.04.001. Epub 2022 Apr 25.
5
A comprehensive review on sarilumab in COVID-19.关于沙利鲁单抗治疗 COVID-19 的全面综述。
Expert Opin Biol Ther. 2021 May;21(5):615-626. doi: 10.1080/14712598.2021.1847269. Epub 2020 Nov 25.
6
Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).托珠单抗和瑞德西韦联合治疗 COVID-19 孕妇。
Obstet Gynecol. 2020 Nov;136(5):1025-1029. doi: 10.1097/AOG.0000000000004050.
7
Treatment strategies of COVID-19: A rheumatology perspective.COVID-19 的治疗策略：风湿病学视角。
Eur J Intern Med. 2022 Aug;102:17-23. doi: 10.1016/j.ejim.2022.05.014. Epub 2022 May 12.
8
Feasibility of tocilizumab in ICU patients with COVID-19.托珠单抗用于新冠肺炎重症监护病房患者的可行性。
J Med Virol. 2021 Jan;93(1):46-47. doi: 10.1002/jmv.26110. Epub 2020 Aug 13.
9
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
10
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
引用本文的文献
1
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.瑞德西韦单药及联合其他药物治疗 COVID-19 的疗效和安全性：系统评价和荟萃分析。
BMC Infect Dis. 2023 Oct 9;23(1):672. doi: 10.1186/s12879-023-08525-0.
2
Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.严重急性呼吸综合征冠状病毒2感染：白细胞介素-6及炎症级联反应的作用
World J Virol. 2022 May 25;11(3):113-128. doi: 10.5501/wjv.v11.i3.113.
3
A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 -Signaling and Cellular Infection with SARS-CoV-2.一种可溶性 gp130/Spike-Nanobody 融合蛋白同时阻断白细胞介素 6 信号和 SARS-CoV-2 细胞感染。
J Virol. 2022 Feb 23;96(4):e0162221. doi: 10.1128/JVI.01622-21. Epub 2021 Dec 22.
4
Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2.新型冠状病毒2019感染患者临床实验室参数、治疗方法及预后的回顾性分析
Indian J Clin Biochem. 2022 Oct;37(4):480-486. doi: 10.1007/s12291-021-01009-5. Epub 2021 Nov 10.
5
Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases.托珠单抗成功治疗重症 COVID-19 肺炎：三例系列报道。
Cardiol J. 2021;28(6):979-982. doi: 10.5603/CJ.a2021.0138. Epub 2021 Oct 28.
6
The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas.在得克萨斯州埃尔帕索的新冠病毒患者中，托珠单抗单药治疗与瑞德西韦和托珠单抗联合治疗的应用
Cureus. 2021 Jul 13;13(7):e16351. doi: 10.7759/cureus.16351. eCollection 2021 Jul.
7
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.实地记录：托珠单抗与瑞德西韦联合治疗重症新型冠状病毒肺炎合并细胞因子释放综合征1例
JMIR Public Health Surveill. 2021 May 19;7(5):e27609. doi: 10.2196/27609.
8
The successful management of an elderly Covid-19 infected patient by plasmapheresis.通过血浆置换成功治疗一名感染新冠病毒的老年患者。
Transfus Apher Sci. 2020 Dec;59(6):102924. doi: 10.1016/j.transci.2020.102924. Epub 2020 Aug 25.
9
Management of SARS-CoV-2 pneumonia.SARS-CoV-2 肺炎的管理。
J Med Virol. 2021 Mar;93(3):1276-1287. doi: 10.1002/jmv.26470. Epub 2020 Oct 10.
本文引用的文献
1
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.COVID-19：考虑使用白细胞介素 6 受体拮抗剂治疗 SARS-CoV-2 感染患者的细胞因子风暴综合征。
J Med Virol. 2020 Nov;92(11):2260-2262. doi: 10.1002/jmv.26078. Epub 2020 Jun 19.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
5
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
6
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
Zotero 插件